BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35082531)

  • 1. Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade.
    Zelic R; Giunchi F; Fridfeldt J; Carlsson J; Davidsson S; Lianas L; Mascia C; Zugna D; Molinaro L; Vincent PH; Zanetti G; Andrén O; Richiardi L; Akre O; Fiorentino M; Pettersson A
    Clin Epidemiol; 2022; 14():59-70. PubMed ID: 35082531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
    Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
    Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
    Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?
    Ross HM; Kryvenko ON; Cowan JE; Simko JP; Wheeler TM; Epstein JI
    Am J Surg Pathol; 2012 Sep; 36(9):1346-52. PubMed ID: 22531173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer.
    Samaratunga H; Delahunt B; Yaxley J; Srigley JR; Egevad L
    Scand J Urol; 2016 Oct; 50(5):325-9. PubMed ID: 27415753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue.
    Gottipati S; Warncke J; Vollmer R; Humphrey PA
    Am J Surg Pathol; 2012 Jun; 36(6):900-7. PubMed ID: 22367295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
    Shah RB; Magi-Galluzzi C; Han B; Zhou M
    Am J Surg Pathol; 2010 Apr; 34(4):470-7. PubMed ID: 20182345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
    Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
    Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.
    Offermann A; Hohensteiner S; Kuempers C; Ribbat-Idel J; Schneider F; Becker F; Hupe MC; Duensing S; Merseburger AS; Kirfel J; Reischl M; Lubczyk V; Kuefer R; Perner S
    Front Med (Lausanne); 2017; 4():157. PubMed ID: 29034236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.
    Srigley JR; Delahunt B; Samaratunga H; Billis A; Cheng L; Clouston D; Evans A; Furusato B; Kench J; Leite K; MacLennan G; Moch H; Pan CC; Rioux-Leclercq N; Ro J; Shanks J; Shen S; Tsuzuki T; Varma M; Wheeler T; Yaxley J; Egevad L
    Pathology; 2019 Aug; 51(5):463-473. PubMed ID: 31279442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?
    Montironi R; Cheng L; Cimadamore A; Mazzucchelli R; Scarpelli M; Santoni M; Massari F; Lopez-Beltran A
    Transl Androl Urol; 2021 Mar; 10(3):1530-1540. PubMed ID: 33850787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
    Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
    Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.
    Montironi R; Cimadamore A; Gasparrini S; Mazzucchelli R; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):685-693. PubMed ID: 29699428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the 2005 International Society of Urological Pathology Gleason grading consensus on active surveillance for prostate cancer.
    Ramakrishnan VM; Bossert K; Singer G; Lehmann K; Hefermehl LJ
    Cent European J Urol; 2017; 70(4):344-348. PubMed ID: 29410883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.
    Verhoef EI; Kweldam CF; Kümmerlin IP; Nieboer D; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
    Histopathology; 2018 Apr; 72(5):760-765. PubMed ID: 29094386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.
    Helpap B; Ringli D; Tonhauser J; Poser I; Breul J; Gevensleben H; Seifert HH
    Pathol Oncol Res; 2016 Apr; 22(2):349-56. PubMed ID: 26563277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.